A Hierarchical Composite Endpoint for CKD Progression in Patients with FSGS
Our findings suggest that a CKD progression HCE, which integrates established CKD endpoints and eGFR slope, provides a sensitive and efficient measure to assess treatment effects in patients with FSGS. Validation of the HCE in prospective clinical trials will support its implementation.
Authors
- Niels Jongs (ORCID: https://orcid.org/0000-0002-0882-3656)
- Dustin J. Little (ORCID: https://orcid.org/0000-0002-4201-0237)
- Roberto D. Toto
- Glenn M Chertow
- C. David Sjostrom
- Ricardo Correa-Rotter
- Peter Rossing
- David C. Wheeler
- Hiddo J.L. Heerspink
Institutions
- University Medical Center Groningen (NL)
- Steno Diabetes Centers (DK)
- University of Groningen (NL)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- The George Institute for Global Health (AU)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- University College London (GB)
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Clinical Journal of the American Society of Nephrology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.2215/cjn.0000000994
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00